india glycols has transferred Senior Managerial Personnel (SMP) Akshay Bansal to its wholly owned subsidiary, Ennature Bio Pharma Limited (EBL), effective July 30, 2026. Consequently, Bansal ceased to be an SMP of the parent company from the close of business hours on July 30, 2026. The transfer is part of a broader organizational restructuring linked to the Scheme of Arrangement between India Glycols and EBL, aimed at addressing specific regulatory observations issued by stock exchanges.

The Board of Directors of EBL approved the appointment of Bansal as Additional Director (Executive Director) and Key Managerial Personnel during its meeting on July 31, 2026. His appointment is effective from July 31, 2026, for a term of five consecutive years, extending until July 30, 2031, subject to shareholder approval. This disclosure serves as a material update in response to Observation Letters received from the National Stock Exchange of India Limited (NSE) dated November 17, 2025, and BSE Limited dated November 19, 2025.

Regulatory Compliance and Disclosures

The intimation was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, read with Para A of Part A of Schedule III and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The filing confirms that Bansal is not debarred from holding the office of Director by virtue of any SEBI order or other authority, in compliance with BSE Circular LIST/COMP/14/2018-19 and NSE Circular NSE/CML/2018/24 dated June 20, 2018.

Executive Profile

Akshay Bansal brings 26 years of experience across the pharmaceuticals, nutraceuticals, and nicotine industries. Prior to this appointment, he served as Head – Sales & Marketing of the Ennature Bio Pharma Division at India Glycols Limited. His professional background includes roles at Mankind Pharma Ltd., Glenmark Generics Ltd., Dishman Group, Alembic Pharmaceuticals Ltd., and Orchid Pharma.

Bansal holds a graduate degree in Hospital Administration and an MBA from Devi Ahilya University, Indore. He also completed a Certificate Programme in General Management (CPGM) from the Institute of Management Studies, Lucknow. His expertise spans manufacturing operations, international commercial strategy, supply chain management, and business development.

India Glycols Limited has formally notified stock exchanges of its 42nd Annual General Meeting (AGM), scheduled for Wednesday, August 19, 2026, at 11:00 AM IST, to be conducted via Video Conferencing or Other Audio Visual Means (VC/OAVM). The company filed the AGM notice along with its Annual Report for FY 2025-26 with BSE Limited and the National Stock Exchange of India Limited on July 24, 2026, pursuant to Regulations 30 and 34 of the SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015. The deemed venue for the AGM shall be the company's registered office at A-1, Industrial Area, Bazpur Road, Kashipur-244713, Distt. Udham Singh Nagar, Uttarakhand.

AGM Agenda and E-Voting Details

The AGM will transact both ordinary and special business. Key items on the agenda include adoption of audited standalone and consolidated financial statements for FY 2025-26, confirmation of the interim dividend of ₹7.50 per equity share of ₹5 each as the final dividend for FY26, and re-appointment of Alok Singhal (DIN: 10359043) as a Director retiring by rotation. As special business, members will consider ratification of remuneration of ₹4,50,000/- (plus applicable taxes and out-of-pocket expenses) payable to M/s R.J. Goel & Co., Cost Accountants, for FY 2026-27.

The company is providing e-voting facilities through National Securities Depository Limited (NSDL). The cut-off date for determining voting rights is Wednesday, August 12, 2026. Remote e-voting will commence on Saturday, August 15, 2026 (9:00 AM) and end on Tuesday, August 18, 2026 (5:00 PM). Members wishing to speak at the AGM may register as speakers by sending requests to compliance.officer@indiaglycols.com between Tuesday, August 11, 2026 (9:00 AM) and Friday, August 14, 2026 (5:00 PM).

FY26 Financial Performance

The AGM comes against the backdrop of a strong financial performance in FY 2025-26. India Glycols recorded its highest-ever gross revenue of ₹9,870 crore on a standalone basis, compared to ₹9,052 crore in FY 2024-25, reflecting growth of over 9%. Net revenue increased from ₹3,782 crore to ₹4,254 crore, a growth of over 12%. Net profit after tax surged over 56% to ₹282 crore from ₹180 crore in the previous year. The company also successfully completed a capital raising of ₹466.99 crore through a preferential issue of equity shares during the year.

On a segment-wise basis, Potable Spirits remained the dominant revenue contributor at 70.69% of gross revenue (₹6,946 crore), followed by Power Alcohol/Bio-Fuel at 14.96% (₹1,470 crore), Bio-Based Specialities and Performance Chemicals at 12.23% (₹1,202 crore), and Ennature Biopharma at 2.12% (₹208 crore). The Bio-Fuels segment delivered revenue growth of over 40%, while the Potable Spirits division registered gross sales growth of over 7%.

Dividend and Shareholder Actions

The Board declared an interim dividend of ₹7.50 per equity share of ₹5 each (150%) for FY 2025-26, with a record date of March 23, 2026. The Board has not recommended any additional final dividend; accordingly, the interim dividend shall be treated as the final dividend for FY26, with total dividend outgo of ₹50.27 crore. As per SEBI Master Circular No. HO/38/13/(4)2026-MIRSD-POD/I/4298/2026 dated February 6, 2026, dividend payments are mandated to be made only through electronic mode. Shareholders are requested to update their KYC and bank details with their Depository Participants or the Registrar and Transfer Agent, MCS Share Transfer Agent Limited, to ensure timely receipt of dividends.

During FY 2025-26, the company transferred ₹21,01,448/- related to final dividend for FY 2017-18 to the Investor Education and Protection Fund (IEPF). Additionally, 1,10,434 equity shares on which dividend remained unpaid/unclaimed for seven consecutive years were transferred to the IEPF Account. Members are advised that the due date for transfer of unclaimed/unpaid final dividend for FY 2018-19 and the concerned shares is September 19, 2026.

Corporate Governance and Demerger Update

In compliance with Regulation 36(1)(b) of the SEBI LODR Regulations, the company has sent letters containing web-links to access the Annual Report for FY 2025-26 to shareholders without registered email addresses. The Annual Report is also available on the company's website at https://www.indiaglycols.com/wp-content/uploads/annual-report-2025-26.pdf .

The Scheme of Arrangement involving the demerger of the Bio Pharma Undertaking into Ennature Bio Pharma Limited and the Spirits and Biofuel Undertaking into IGL Spirits Limited remains pending before the National Company Law Tribunal (NCLT), Allahabad Bench. The NCLT admitted the Second Motion Petition vide its order dated April 9, 2026, and the matter is scheduled for further hearing. The appointed date for the Scheme of Arrangement is April 1, 2026. Upon the Scheme becoming effective, both Ennature Bio Pharma Limited and IGL Spirits Limited are expected to be listed on NSE and BSE, subject to requisite regulatory approvals.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE560A01023/25a888c8-7a30-4e8a-89ee-346460c29b72.pdf